Animal studies have failed to reveal evidence of teratogenicity (clindamycin). Animal studies have revealed teratogenicity, embryotoxicity and increased abortion rates (tretinoin). There are no controlled data in human pregnancy.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended in pregnancy, especially during the first trimester, and in women of childbearing potential.
-According to some authorities: Use is contraindicated.

AU TGA pregnancy category: D
US FDA pregnancy category: C

See references

Oral and parenteral administration of clindamycin has been reported to appear in breast milk. Additionally, orally administered retinoids and their metabolites have been reported to be secreted in breast milk.

Use is not recommended.

Excreted into human milk: Unknown (clindamycin, tretinoin)
Excreted into animal milk: Data not available (clindamycin, tretinoin)

Comments: The effects in the nursing infant are unknown.

See references